clinical trial · NCT04972227
Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia
SchizophreniaCY6463Placebo
brief summary
The primary objective of this study is to evaluate the safety and tolerability of CY6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen
started
Sep 10, 2021
primary completion
Apr 18, 2022
completion
Apr 18, 2022
last updated
Aug 13, 2024
official title
A Double-blinded, Randomized, Placebo-controlled, Multiple-ascending-dose Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol